Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allegra D in Indian participants with allergic rhinitis
NCT05720455Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fexofenadine + pseudoephedrine in allergic rhinitis (AR), sponsored by Sanofi. Primary endpoints: Treatment-Emergent Adverse Events at 16 days and Treatment-Emergent Serious Adverse Events at 16 days. Started Jun 2025; status: completed.
02
Drugs
fexofenadine + pseudoephedrine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05720455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720455.